takeaway ew meet
last week met ew cfo ir team ew corpor headquart
note follow takeaway
ask ew rais full year guidanc much earli year ew
point increment momentum saw smaller us center
ew comment center open patient follow work
done make sure popul support new center detect increment
caution manag regard reason rais guidanc earli
year despit histor volatil busi ew comment
littl model ultra centera ew point reason
assum small contribut two product intent
hold back launch centera focu primarili key account
littl presenc regard ultra ew guidanc call launch europ ew
chang guidanc compani take opportun highlight
approv process europ becom challeng med-tech late
small delay would issu ew view given strong core
model consider view ew guidanc suggest potenti
ep upsid guidanc given tavr profit margin ask ew
flow math manag reiter quantifi increment
spend contempl guidanc increment spend focus three main
area far tell direct consum type spend ii spend mitral
tricuspid program iii spend new manufactur capac given
model increment tavr sale manag would
spend away keep ep in-lin guidanc math
given tavr margin ew clearli spend plan doubt increment
spend add lastli ew also suggest royalti
closer level roughli realiz
make guidanc rais even impress ew guid meaning
deceler revenue growth despit
season trend usual stronger note updat
model earn reiter buy rate ep
line guidanc ep
net dbt
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
edward lifesci leader emerg
field transcathet heart valv replac
one visibl innov excit
market medic devic sector
ew heart valv busi gener
compani total revenu critic care
busi account total sale
almost attent focus
compani today due on-going pioneer
role develop transcathet heart valv
next year believ
new product opportun med-tech
similar potenti size tavi market ew
stand-alon name ew signific pot
approv pipelin updat relat mitral
believ tavi stand alongsid coronari
stent core technolog catheter
lab futur
po base ew ep premium peer trade
earn think ew trade signific premium peer due
belief potenti upsid mitral strong us tavr market growth tavr
indic expans potenti valu compani next gener tavi valv
downsid risk price object tavi market develop risk rel
street high expect competit risk relat ew core tavi busi
risk market opportun technolog could smaller
assum upsid risk price object failur ew competit come
market given limit data set avail date potenti deeper
penetr market larger market opportun model
untreat high low moder risk patient seek tavi given less invas
bob hopkin herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
